ザレルト市場：市場規模、予測、市場洞察- 2032年

ザレルトは、血栓の治療と予防を目的とした経口抗凝固薬です。アスピリンとの併用により、症候性PADにより最近下肢血行再建術を受けた患者を含む成人PAD患者において、主要な血栓性血管イベント（心筋梗塞、虚血性脳卒中、急性四肢虚血、血管に起因する大断端）のリスクを軽減することが適応となります。ザレルトは、血液凝固を低下させる血液サラサラ薬（抗凝固薬）であるため、出血を引き起こす可能性があり、重篤で死に至ることもあります。そのため、この薬にはFDAから箱書きの警告が付けられています。

ザレルトは、冠動脈疾患（CAD）とPAD（LER後のPAD患者を含む）の両方に適応がある最初で唯一の治療薬です。さらに、急性四肢虚血や切断などの重大な血栓性イベントのリスクが高いPAD患者において、有意な効果を示した20年来の唯一の抗凝固薬でもあります。

ザレルトはFXaの選択的阻害薬であり、活性には補酵素（抗トロンビンIIIなど）を必要としません。リバーロキサバンは遊離FXaおよびプロトロンビナーゼ活性を阻害します。リバーロキサバンは血小板凝集に直接作用しませんが、トロンビンによって誘導される血小板凝集を間接的に阻害します。FXaを阻害することにより、リバーロキサバンはトロンビンの生成を減少させます。

今後数年間で、末梢動脈疾患（PAD）の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、ザレルトの優位性に影響を与える可能性のある機会を模索しています。PAD治療薬としては、他の新興製品がザレルトと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国における末梢動脈疾患（PAD）治療薬のザレルト市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 末梢動脈疾患（PAD）におけるザレルトの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ザレルト市場評価

• PADにおけるザレルトの市場見通し
• 米国と日本の分析
  • 米国と日本におけるPAD治療薬ザレルトの市場規模
• 国別市場分析
  • 米国
  • 日本

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: XARELTO, Clinical Trial Description, 2023
• Table 2: XARELTO, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: XARELTO Market Size in the US and Japan, in USD million (2019-2032)
• Table 6: XARELTO Market Size in the US, in USD million (2019-2032)
• Table 7: XARELTO Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: XARELTO Market Size in the US and Japan, USD million (2019-2032)
• Figure 2: XARELTO Market Size in the United States, USD million (2019-2032)
• Figure 3: XARELTO Market Size in Japan, USD million (2019-2032)

"XARELTO Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about XARELTO for Peripheral Artery Disease (PAD) in the United States and Japan. A detailed picture of the XARELTO for PAD in the United States and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the XARELTO for PAD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XARELTO market forecast analysis for PAD in the US and Japan, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PAD.

Drug Summary:

XARELTO is an oral anticoagulant for the treatment and prevention of blood clots. In combination with aspirin, it is indicated to reduce the risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology) in adult patients with PAD, including patients who have recently undergone a lower extremity revascularization procedure due to symptomatic PAD. XARELTO can cause bleeding, which can be serious and may lead to death, as it is a blood thinner medicine (anticoagulant) that lowers blood clotting. Thus the drug has a boxed warning from FDA.

XARELTO is the first and only therapy indicated for both coronary artery disease (CAD) and PAD, including PAD patients post-LER. In addition, it is also the only anticoagulant in 20 years to show significant benefit in patients with PAD who remain at high risk for major thrombotic events, including acute limb ischemia and amputation.

• Dosage and administration

The recommended dose of XARELTO is 2.5 mg orally twice daily with or without food, in combination with aspirin (75-100 mg) once daily. No dose adjustment was needed for renal considerations.

• Mechanism of action

XARELTO is a selective inhibitor of FXa, and it does not require a cofactor (such as anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity; rivaroxaban does not directly affect platelet aggregation but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the XARELTO description, mechanism of action, dosage and administration, research and development activities in Peripheral Artery Disease (PAD).
• Elaborated details on XARELTO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the XARELTO research and development activities in PAD across the United States and Japan.
• The report also covers the patents information with expiry timeline around XARELTO.
• The report contains forecasted sales of XARELTO for PAD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for PAD.
• The report also features the SWOT analysis with analyst views for XARELTO in PAD.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XARELTO Analytical Perspective by DelveInsight

• In-depth XARELTO Market Assessment

This report provides a detailed market assessment of XARELTO for Peripheral Artery Disease (PAD) in the United States and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• XARELTO Clinical Assessment

The report provides the clinical trials information of XARELTO for PAD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Peripheral Artery Disease (PAD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XARELTO dominance.
• Other emerging products for PAD are expected to give tough market competition to XARELTO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XARELTO in PAD.
• Our in-depth analysis of the forecasted sales data of XARELTO from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XARELTO in PAD.

Key Questions:

• What is the product type, route of administration and mechanism of action of XARELTO?
• What is the clinical trial status of the study related to XARELTO in Peripheral Artery Disease (PAD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XARELTO development?
• What are the key designations that have been granted to XARELTO for PAD?
• What is the forecasted market scenario of XARELTO for PAD?
• What are the forecasted sales of XARELTO in the US and Japan?
• What are the other emerging products available and how are these giving competition to XARELTO for PAD?
• Which are the late-stage emerging therapies under development for the treatment of PAD?

Table of Contents

1. Report Introduction

2. XARELTO Overview in PAD

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. XARELTO Market Assessment

• 5.1. Market Outlook of XARELTO in PAD
• 5.2. The US and Japan Analysis
  • 5.2.1. Market Size of XARELTO in the US and Japan for PAD
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of XARELTO in the United States for PAD
  • 5.3.2. Market Size of XARELTO in Japan for PAD

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options